AbbVie Inc. ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. The study was unable to meet its primary endpoint of improving progression-free survival (PFS) or overall survival (OS) benefit amid the given patient population.

The phase III RESOLVE study investigated the efficacy of Imbruvica in combination

Read More At Article Source | Article Attribution